Literature DB >> 123252

Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.

P C Harpel, T E Hugli, N R Cooper.   

Abstract

The function and several of the structural features of the C1 inactivator protein isolated from the plasma of a mother and daughter with the variant form of hereditary angioneurotic edema have been examined. These abnormal inhibitors shared immunologic identity with the normal C1 inactivator protein; however, they were inactive in inhibiting the functional activity of C1s. Analysis of the abnormal inhibitors by sodium dodecyl sulfate (SDS) acrylamide gel electrophoresis suggested that each consisted of a single polypeptide chain, the mobility of which was slower than that of the normal C1 inactivator. The apparent molecular weight of the patients' inhibitors was 109,000 daltons as contrasted to 105,000 daltons, that of the normal C1 inactivator. The abnormal inhibitors failed to form a complex with C1s or plasmin as analyzed by SDS-acrylamide gels. The large proteolytic derivatives resulting from the plasmin- and trypsin-induced degradation of the abnormal inhibitors were approximately 3,000 daltons heavier than the corresponding products derived from normal C1 inactivator. Thus, the structural abnormality identified appeared to be a property of the core molecule. Treatment of the inhibitors with neuraminidase failed to demonstrate a difference between the normal and patient-derived C1 inactivator molecule. Neither were major differences found between the amino acid composition of the defective and normal inhibitors; however, the acidic amino acids tended to be higher in the patients' inhibitors, and the phenylalanine content lower. Thus, these studies have identified both structural and functional abnormalities in the C1 inactivator protein isolated from two related patients with hereditary angioneurotic edema. Examination of the interaction between endopeptidases and the inhibitors has further delineated the abnormal structural features.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 123252      PMCID: PMC301789          DOI: 10.1172/JCI107968

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

Authors:  V H DONALDSON; R R EVANS
Journal:  Am J Med       Date:  1963-07       Impact factor: 4.965

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS.

Authors:  F S ROSEN; J PENSKY; V DONALDSON; P CHARACHE
Journal:  Science       Date:  1965-05-14       Impact factor: 47.728

4.  [Isolation and characterization of C1-Inactivator from human plasma].

Authors:  H Haupt; N Heimburger; T Kranz; H G Schwick
Journal:  Eur J Biochem       Date:  1970-12

5.  Measurement of molecular weights by electrophoresis on SDS-acrylamide gel.

Authors:  K Weber; J R Pringle; M Osborn
Journal:  Methods Enzymol       Date:  1972       Impact factor: 1.600

6.  The molecular weights of vertebrate histones exploiting a modified sodium dodecyl sulfate electrophoretic method.

Authors:  S Panyim; R Chalkley
Journal:  J Biol Chem       Date:  1971-12-25       Impact factor: 5.157

7.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

8.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

9.  Physicochemical and biological properties of human and canine plasmins.

Authors:  Y Takeda; M Nakabayashi
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema.

Authors:  F S Rosen; C A Alper; J Pensky; M R Klemperer; V H Donaldson
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

View more
  6 in total

1.  Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.

Authors:  M Quastel; R Harrison; M Cicardi; C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

2.  Rapid and sensitive techniques for identification and analysis of 'reactive-centre' mutants of C1-inhibitor proteins contained in type II hereditary angio-oedema plasmas.

Authors:  K S Aulak; R S Harrison
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

3.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

4.  Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon.

Authors:  T Ariga; T Igarashi; N Ramesh; R Parad; M Cicardi; A E Davis
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

5.  Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.

Authors:  K S Aulak; P A Pemberton; F S Rosen; R W Carrell; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

6.  Special vulnerability of somatic niche cells to transposable element activation in Drosophila larval ovaries.

Authors:  Olesya A Sokolova; Elena A Mikhaleva; Sergey L Kharitonov; Yuri A Abramov; Vladimir A Gvozdev; Mikhail S Klenov
Journal:  Sci Rep       Date:  2020-01-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.